KRSA · Korsana Biosciences, Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-04-01 |
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease |
| 2026-02-17 |
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development – –Remain On Track to Initiate CYC-126's Phase 2 |
| 2026-01-05 |
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 |
| 2025-09-23 |
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass. , Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. |
| 2024-12-17 |
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat CAMBRIDGE, Mass. , Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its |
| 2024-08-07 |
Regina Graul, Ph.D., Promoted to Chief Executive Officer
CAMBRIDGE, Mass. , Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul , Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December |
| 2023-12-04 |
Cyclerion Appoints Regina Graul, Ph.D., as President
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht , Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding |
| 2023-11-30 |
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
- Dina Katabi , Ph.D.: World leader in healthcare AI applications at MIT ; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins : Seasoned biopharma executive possessing |
| 2023-07-31 |
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion |
| 2023-06-01 |
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass. , June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-26 | Annual Shareholder Meeting | Shareholder meeting |
| 2026-04-01 | Earnings conference call (announced in 8-K) | Earnings call |
| 2026-01-06 | Medsteer Collaboration Agreement and Business Update | Event |
| 2025-09-24 | Pioneering a New Era in Neuropsychiatric Therapies | Event |
| 2022-07-28 | Clinical Data Update from Study of CY6463 in CIAS | Event |
| 2022-06-28 | CY6463 MELAS Study Clinical Data Update Webinar (hosted by UMDF) | Event |
| 2022-06-10 | UMDF Mitochondrial Medicine 2022 Symposium: Clinical Trial Updates with Discussion Panel Topline CY6463 Clinical Data in MELAS | Event |
| 2021-11-18 | Jefferies London Healthcare Conference | Conference |
| 2021-09-30 | Cantor Fitzgerald Virtual Global Healthcare Conference | Conference |
| 2021-09-13 | H.C. Wainwright 23rd Annual Global Investment Conference | Conference |
| 2021-08-26 | Biomarker for Alzheimer’s Disease Summit | Event |